相似文献
1
V3 tip determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A human immunodeficiency virus (HIV-1) envelope glycoproteins.
J Virol. 2023 Nov 30;97(11):e0117123. doi: 10.1128/jvi.01171-23. Epub 2023 Oct 27.
2
Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
J Virol. 2022 Sep 14;96(17):e0063622. doi: 10.1128/jvi.00636-22. Epub 2022 Aug 18.
3
Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
J Virol. 2017 Jan 18;91(3). doi: 10.1128/JVI.01880-16. Print 2017 Feb 1.
4
Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer.
J Virol. 2019 Oct 15;93(21). doi: 10.1128/JVI.01197-19. Print 2019 Nov 1.
5
Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity.
Proc Natl Acad Sci U S A. 2023 Mar 28;120(13):e2222073120. doi: 10.1073/pnas.2222073120. Epub 2023 Mar 24.
6
Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.
J Virol. 2016 Apr 29;90(10):5031-5046. doi: 10.1128/JVI.03211-15. Print 2016 May 15.
7
Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
Acc Chem Res. 2014 Apr 15;47(4):1228-37. doi: 10.1021/ar4002735. Epub 2014 Feb 6.
8
Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.
PLoS Pathog. 2009 Apr;5(4):e1000360. doi: 10.1371/journal.ppat.1000360. Epub 2009 Apr 3.
9
Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.
J Virol. 2020 May 4;94(10). doi: 10.1128/JVI.00148-20.
10
A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120.
J Virol. 2025 Apr 15;99(4):e0226724. doi: 10.1128/jvi.02267-24. Epub 2025 Mar 27.
引用本文的文献
1
Stoichiometry of HIV-1 Envelope Glycoprotein Protomers with Changes That Stabilize or Destabilize the Pretriggered Conformation.
bioRxiv. 2024 Oct 25:2024.10.25.620268. doi: 10.1101/2024.10.25.620268.
2
Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics.
J Virol. 2024 Oct 22;98(10):e0096024. doi: 10.1128/jvi.00960-24. Epub 2024 Sep 4.
3
Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs.
iScience. 2024 May 28;27(7):110141. doi: 10.1016/j.isci.2024.110141. eCollection 2024 Jul 19.
4
Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in presence of CD4-mimetics.
medRxiv. 2024 Jun 4:2024.06.02.24308281. doi: 10.1101/2024.06.02.24308281.
本文引用的文献
1
Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation.
J Virol. 2023 Sep 28;97(9):e0059223. doi: 10.1128/jvi.00592-23. Epub 2023 Sep 11.
2
Piperidine CD4-Mimetic Compounds Expose Vulnerable Env Epitopes Sensitizing HIV-1-Infected Cells to ADCC.
Viruses. 2023 May 17;15(5):1185. doi: 10.3390/v15051185.
3
Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity.
Proc Natl Acad Sci U S A. 2023 Mar 28;120(13):e2222073120. doi: 10.1073/pnas.2222073120. Epub 2023 Mar 24.
4
Characterization of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformational States on Infectious Virus Particles.
J Virol. 2023 Mar 30;97(3):e0185722. doi: 10.1128/jvi.01857-22. Epub 2023 Feb 23.
5
Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
J Virol. 2022 Sep 14;96(17):e0063622. doi: 10.1128/jvi.00636-22. Epub 2022 Aug 18.
6
Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation.
J Virol. 2022 Apr 27;96(8):e0166821. doi: 10.1128/jvi.01668-21. Epub 2022 Mar 28.
7
Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can Be Minimized by Distant State 1-Stabilizing Changes.
J Virol. 2022 Apr 13;96(7):e0187821. doi: 10.1128/jvi.01878-21. Epub 2022 Mar 15.
8
Characterization of Near Full-Length Transmitted/Founder HIV-1 Subtype D and A/D Recombinant Genomes in a Heterosexual Ugandan Population (2006-2011).
Viruses. 2022 Feb 7;14(2):334. doi: 10.3390/v14020334.
9
Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir.
Cell Host Microbe. 2021 Jun 9;29(6):904-916.e6. doi: 10.1016/j.chom.2021.04.014. Epub 2021 May 20.
10
Functional Anatomy of the Trimer Apex Reveals Key Hydrophobic Constraints That Maintain the HIV-1 Envelope Spike in a Closed State.
mBio. 2021 Mar 30;12(2):e00090-21. doi: 10.1128/mBio.00090-21.
Zotero 插件